SPRO
Closed
Spero Therapeutics Inc
2.9
0.0 (0.00%)
Last Update: 01 Jul 2025 23:18:00
Yesterday: 2.9
Day's Range: 2.9 - 2.95
Send
sign up or login to leave a comment!
When Written:
1.56
Spero Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing novel treatments for multi-drug resistant bacterial infections. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Spero Therapeutics' lead product candidate is SPR994, an oral antibiotic designed to treat complicated urinary tract infections (cUTIs) caused by multi-drug resistant gram-negative bacteria. The company is also developing SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial (NTM) infections, as well as SPR206, an intravenous antibiotic for the treatment of gram-negative bacterial infections.
Spero Therapeutics has partnerships with other pharmaceutical companies, including Pfizer, to develop new antibiotics. The company has received funding from various sources, including the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).
As of 2021, Spero Therapeutics has a market capitalization of over $300 million and is traded on the Nasdaq stock exchange under the ticker symbol "SPRO".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Spero Therapeutics' lead product candidate is SPR994, an oral antibiotic designed to treat complicated urinary tract infections (cUTIs) caused by multi-drug resistant gram-negative bacteria. The company is also developing SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial (NTM) infections, as well as SPR206, an intravenous antibiotic for the treatment of gram-negative bacterial infections.
Spero Therapeutics has partnerships with other pharmaceutical companies, including Pfizer, to develop new antibiotics. The company has received funding from various sources, including the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA).
As of 2021, Spero Therapeutics has a market capitalization of over $300 million and is traded on the Nasdaq stock exchange under the ticker symbol "SPRO".
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!